Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

VANTA BIOSCIENCE LTD.

NSE : NABSE : 540729ISIN CODE : INE695X01011Industry : Business SupportHouse : Private

BSE25.861.23 (+4.99 %)

PREV CLOSE ( ) 24.63

OPEN PRICE ( ) 25.86

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 20250

TODAY'S LOW / HIGH ( )25.85 25.86

52 WK LOW / HIGH ( ) 19.0856

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Operational & Financial Ratios

Earnings Per Share (Rs)

-3.67

-10.27

0.14

0.71

1.59

CEPS(Rs)

-6.51

-12.32

2.30

2.69

3.49

DPS(Rs)

0.00

Book NAV/Share(Rs)

24.08

27.75

38.03

37.89

37.18

Tax Rate(%)

2.49

-1.77

41.03

23.91

24.52

Margin Ratios

Core EBITDA Margin(%)

13.50

-38.14

35.80

39.31

30.89

EBIT Margin(%)

-31.65

-69.74

26.58

27.18

23.26

Pre Tax Margin(%)

-90.78

-163.53

2.36

5.87

9.49

PAT Margin (%)

-88.52

-166.43

1.39

4.47

7.16

Cash Profit Margin (%)

-42.27

-123.88

14.98

16.93

15.57

Performance Ratios

ROA(%)

-10.12

-12.57

0.18

0.76

2.31

ROE(%)

-52.62

-50.31

0.56

1.89

4.43

ROCE(%)

-4.08

-6.10

4.00

5.42

8.62

Asset Turnover(x)

0.11

0.08

0.13

0.17

0.32

Sales/Fixed Asset(x)

0.14

0.12

0.26

0.36

0.67

Working Capital/Sales(x)

-1.70

-2.51

44.16

1.97

1.42

Efficiency Ratios

Fixed Capital/Sales(x)

6.98

8.62

3.83

2.81

1.50

Receivable days

95.72

89.94

59.32

61.93

38.14

Inventory Days

275.51

418.55

320.25

432.17

300.03

Payable days

2480.59

1287.00

761.36

213.02

146.72

Valuation Parameters

PER(x)

0.00

786.33

228.87

57.18

PCE(x)

-9.83

-4.67

47.79

60.53

26.09

Price/Book(x)

2.66

2.07

2.89

4.30

2.45

Yield(%)

0.00

EV/Net Sales(x)

10.42

14.88

11.77

13.88

5.42

EV/Core EBITDA(x)

71.41

-54.70

29.29

34.22

16.66

EV/EBIT(x)

-32.93

-21.33

44.26

49.91

22.68

EV/CE(x)

1.33

1.25

1.40

1.95

1.53

M Cap / Sales

4.15

5.78

7.16

10.48

4.18

Growth Ratio

Net Sales Growth(%)

54.92

-35.22

-1.30

-28.63

13.85

Core EBITDA Growth(%)

183.16

-143.86

-2.23

-11.13

27.88

EBIT Growth(%)

29.69

-269.96

-5.62

-17.06

17.85

PAT Growth(%)

17.60

-7855.72

-69.96

-55.73

45.14

EPS Growth(%)

64.26

-7449.46

-80.38

-55.25

44.23

Financial Stability Ratios

Total Debt/Equity(x)

4.02

3.26

1.87

1.50

0.74

Current Ratio(x)

0.75

0.86

1.02

1.34

1.99

Quick Ratio(x)

0.42

0.46

0.51

0.69

0.60

Interest Cover(x)

-0.54

-0.74

1.10

1.28

1.69

Total Debt/Mcap(x)

1.51

1.57

0.65

0.35

0.30